Captrust Financial Advisors Sells 8,909 Shares of BioNTech SE (NASDAQ:BNTX)

Captrust Financial Advisors lowered its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 70.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,678 shares of the company's stock after selling 8,909 shares during the quarter. Captrust Financial Advisors' holdings in BioNTech were worth $437,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock worth $74,000 after acquiring an additional 111 shares during the last quarter. Blue Trust Inc. raised its position in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after purchasing an additional 388 shares during the period. Gallacher Capital Management LLC lifted its stake in shares of BioNTech by 12.1% during the 2nd quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company's stock valued at $294,000 after buying an additional 395 shares in the last quarter. TD Asset Management Inc boosted its holdings in BioNTech by 6.1% in the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company's stock worth $612,000 after buying an additional 435 shares during the period. Finally, Planning Capital Management Corp grew its stake in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after buying an additional 450 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on BNTX. Bank of America increased their target price on BioNTech from $125.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, September 16th. TD Cowen cut their target price on BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research note on Tuesday, November 5th. HSBC upped their price target on BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a research report on Monday, October 7th. Morgan Stanley upgraded shares of BioNTech from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Finally, Wells Fargo & Company started coverage on BioNTech in a research report on Wednesday. They issued an "overweight" rating and a $170.00 price objective on the stock. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $140.76.

BioNTech Trading Down 0.3 %

NASDAQ:BNTX traded down $0.31 during trading hours on Friday, reaching $120.38. The company's stock had a trading volume of 586,062 shares, compared to its average volume of 808,448. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a 50-day simple moving average of $113.86 and a 200-day simple moving average of $100.34. The firm has a market capitalization of $28.62 billion, a price-to-earnings ratio of -57.32 and a beta of 0.22.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $514.08 million. During the same period in the previous year, the firm earned $0.73 EPS. The business's quarterly revenue was up 38.9% on a year-over-year basis. Research analysts expect that BioNTech SE will post -3.72 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.